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Abstract
Prostaglandin-endoperoxide synthase 2 (PTGS2), also known as cyclooxygenase 2 (COX-2), plays a critical role in many
normal physiological functions and modulates a variety of pathological conditions. The ability to turn endogenous COX-2
on and off in a reversible fashion, at specific times and in specific cell types, would be a powerful tool in determining its role
in many contexts. To achieve this goal, we took advantage of a recently developed RNA interference system in mice. An
shRNA targeting the Cox2 mRNA 39untranslated region was inserted into a microRNA expression cassette, under the control
of a tetracycline response element (TRE) promoter. Transgenic mice containing the COX-2-shRNA were crossed with mice
encoding a CAG promoter-driven reverse tetracycline transactivator, which activates the TRE promoter in the presence of
tetracycline/doxycycline. To facilitate testing the system, we generated a knockin reporter mouse in which the firefly
luciferase gene replaces the Cox2 coding region. Cox2 promoter activation in cultured cells from triple transgenic mice
containing the luciferase allele, the shRNA and the transactivator transgene resulted in robust luciferase and COX-2
expression that was reversibly down-regulated by doxycycline administration. In vivo, using a skin inflammation-model,
both luciferase and COX-2 expression were inhibited over 80% in mice that received doxycycline in their diet, leading to a
significant reduction of infiltrating leukocytes. In summary, using inducible RNA interference to target COX-2 expression, we
demonstrate potent, reversible Cox2 gene silencing in vivo. This system should provide a valuable tool to analyze cell type-
specific roles for COX-2.
Citation: Zaiss AK, Zuber J, Chu C, Machado HB, Jiao J, et al. (2014) Reversible Suppression of Cyclooxygenase 2 (COX-2) Expression In Vivo by Inducible RNA
Interference. PLoS ONE 9(7): e101263. doi:10.1371/journal.pone.0101263
Editor: Junming Yue, The University of Tennessee Health Science Center, United States of America
Received March 20, 2014; Accepted June 4, 2014; Published July 2, 2014
Copyright:  2014 Zaiss et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This work was supported by National Institutes of Health grant P50 CA086306-08 (HRH). AKZ is the recipient of an American Society of Hematology
(ASH) Scholar Award. SWL is an investigator of the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following competing interests: SWL and JZ are members of the Scientific
Advisory Board and hold equity in Mirimus Inc., a company that has licensed some of the technology reported in this manuscript. The authors’ involvement in
Mirimus Inc. (SWL and JZ) does not alter their adherence to PLOS ONE policies on sharing data and materials.
* Email: hherschman@mednet.ucla.edu
¤a Current address: Research Institute of Molecular Pathology (IMP), Vienna, Austria
¤b Current address: Memorial Sloan-Kettering Cancer Center, New York, New York, New York, United States of America
Introduction
Prostanoids modulate a number of complex biological process-
es, including inflammation and immunity, pregnancy and
parturition, cardiovascular function, temperature regulation,
neurodegeneration and tumor progression [1]. Prostanoid pro-
duction is initiated by the cyclooxygenases (COX); enzymes that
convert arachidonic acid to the unstable intermediate prostaglan-
din H2 (PGH2). PGH2 is then further converted, in cell-specific
pathways, to a variety of products that include a number of
prostaglandins (PGE2, PGF2a, PGD2, etc.), prostacyclin (PGI2) and
thromboxane (TXA2).
Vertebrate species have two Cox genes, Cox1 and Cox2. The
COX-1 and COX-2 enzymes are isoforms, similar in structure,
that catalyze identical reactions. However, they differ in the
regulation of their expression and their biological roles. Most cells
constitutively express the COX-1 isoform. Consequently, COX-1
is thought to play a role in homeostatic functions. In contrast,
COX-2 is not constitutively expressed in most tissues, but is
rapidly induced in many cell types in response to a wide range of
mitogens, cytokines and other stimuli, and is often present in
elevated levels at sites of inflammation and epithelial cancers [2].
The cyclooxygenases are the targets of nearly all commonly
used non-steroidal anti-inflammatory drugs (NSAIDs; e.g., ibu-
profen and aspirin). These drugs inhibit COX-1 and COX-2
enzymatic activity, thereby preventing prostanoid production.
Prostaglandins are recognized as important modulators of the
immune system; COX-2 has been associated with an orchestrating
role in both the induction and resolution of acute inflammation
[3]. COX-2 is also expressed in sterile inflammation, and is
induced by pathogens, but its role in anti-pathogen immune
responses is not well understood [4,5].
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The therapeutic effects of NSAIDs and their side effects, as well
as studies with COX-2 selective inhibitors (e.g., celecoxib) and
with conventional Cox2 knockout mice suggest roles for COX-2 in
a variety of diseases beyond the symptomatic control of pain and
fever. Examples of suggested roles for COX-2 aberrant expression
include problems in female fertility and parturition [6] and in
neurodegenerative diseases such as Alzheimer’s disease and
Parkinson’s disease [7]. Considerable research has also been
devoted to understanding the role of COX-2 in cancer. COX-2
dependent prostanoids contribute to cell proliferation, and
increased COX-2 expression occurs in a wide variety of epithelial
cancers [8]. In particular, the beneficial effects of NSAIDs have
suggested a major role for COX-2 in colon cancer, where this
enzyme is suggested to play modulatory and even causal roles
[9,10].
At what times, and in which subsets of cells, COX-2 expression
is required to either promote or suppress tumorigenesis, infection
and other biological processes is still unclear. A model system in
which spatial, temporal and reversible loss of COX-2 function
could be achieved would, therefore, be of great value in
understanding the roles COX-2 plays in normal and pathophys-
iological conditions.
One way cells achieve targeted modulation of gene expression is
through RNA interference (RNAi). RNAi is an endogenous
mechanism in which short hairpin RNA (shRNA) species
modulate targeted transcripts. In mammals, naturally occurring
shRNAs are usually embedded within a microRNA (miRNA)
backbone [11]. The miRNA is processed to a short hairpin RNA
consisting of a sequence of 21–29 nucleotides, a short loop region
and the reverse complement of the 21–29-nucleotide region. This
short RNA molecule folds back on itself to form a hairpin
structure, which is cleaved into double-stranded RNAs by ‘Dicer’,
an endogenous nuclease. After nuclease digestion the RNA
silencing complex recognizes the shRNA and guides it to
complementary mRNA(s), thereby targeting them for destruction
[12,13]. In this manner, RNAi regulates sequence-specific mRNA
destruction.
Investigator-initiated experimental RNAi gene silencing has
advantages over traditional gene targeting methods, since RNAi
agents act without modifying the target gene. Cullen et al. [14]
demonstrated they could use a scaffold to embed and subsequently
express a synthetic shRNA sequence targeting a gene of interest.
Using the microRNA30 (miR30) precursor RNA as a template,
they substituted miR30 stem sequences with designed shRNAs,
and showed effective target gene inhibition [15]. When shRNAs
are expressed from a tetracycline response element (TRE)
promoter in cells, along with a tetracycline transactivator (tTA
or rtTA) protein, the shRNA can be reversibly expressed in
response to doxycycline (DOX) presence or absence [16,17]. Both
a ‘tet-off’ system, in which the tet-transactivator (tTA) protein
activates the TRE promoter but is inhibited by the administration
of DOX and a ‘tet-on’ system, in which the reverse tet-
transactivator (rtTA) is latent until activated by DOX, are in
common usage for reversible regulation of gene expression [18].
Many mouse lines have been developed that express the tTA (tet
off) or rtTA (tet-on) transactivators from tissue specific promoters,
allowing temporal and reversible control of gene expression in
specific cell types [19].
The ability to reversibly control the location, timing and levels
of COX-2 expression would facilitate the elucidation of the many
and varied COX-2 roles in normal physiology and disease. In this
study we describe the development of a mouse model in which
DOX-regulated expression of a COX-2 targeted shRNA makes it
possible to inactivate endogenous Cox2 gene expression, providing
cell-specific, reversible elimination of COX-2 expression and
function.
Materials and Methods
COX-2 shRNA design and cloning
Potential gene silencing short hairpin RNAs (shRNAs) targeting
COX-2 were designed as described [20]. Predicted shRNAs were
screened against a series of sensor exclusion criteria and cross-
checked against a transcript database to exclude sequences with
similarity to ‘off-target’ genes [20]. Four 22-mer predicted
shRNAs; Cox2.284, Cox2.1082, Cox2.2058 and Cox2.3711 were
identified; numerical designations reflect the first nucleotide
position of the targeted mouse Cox2 mRNA sequence (Fig. 1A).
These shRNA sequences, and their corresponding sense strand
predictions, were synthesized as 97 mers and cloned into the
miR30 shRNA backbone as described previously [21]. These
sequences comprise the common and gene-specific stem and
19 bp loop of the miR30-context to create miR30-adapted
shRNAs specific for Cox2.
Retrovirus vector preparation and shRNA testing
The LMP retroviral vector, a murine stem cell virus (MSCV)-
based vector contains unique XhoI and EcoRI sites within a miR30-
shRNA expression cassette, driven by the viral 59LTR promoter
([17,20] and Fig. 1A). The vector also encodes PGK promoter-
driven puromycin resistance and green fluorescent protein
sequences, separated by an internal ribosome entry site (IRES).
The four XhoI/EcoRI COX-2-shRNAs were cloned into the LMP
vector, and retroviral stocks for the four COX-2-shRNAs and a
retrovirus containing a control shRNA targeting the firefly
luciferase coding sequence were generated by three plasmid co-
transfection using a VSV-G envelope plasmid in HEK293 cells
(ATCC).
To test the ability of the four COX-2 shRNAs to block COX-2
induction at single copy integrated levels, NIH3T3 mouse
embryonic fibroblast cells and RAW264.7 (ATCC) mouse
monocytic leukemia cells were transduced with a viral multiplicity
of infection (MOI) resulting in ,1% GFP-positive cells. Cells
selected with puromycin (2.5 mg/ml) were used to test COX-2
induction 3–5 days later. NIH3T3 cells were cultivated in
DMEM-supplemented with 10% fetal bovine serum (FBS) and
1% penicillin-streptomycin at 37uC in 5% CO2. RAW264.7 cells
were maintained in RPMI 1640 medium with 10% FBS and 1%
penicillin-streptomycin. COX-2 was induced in RAW264.7 cells
by adding bacterial lipopolysaccharide (LPS, Sigma) for four
hours. NIH3T3 cells were starved with 1% FBS over night before
shifting to medium with 20% FBS for six hours to induce COX-2
expression. Cells were washed with PBS and lysed directly in the
culture dish with Passive Lysis Buffer (Promega). For prostaglandin
E2 (PGE2) analyses culture supernatants were harvested, snap
frozen in liquid nitrogen, and assayed collectively by ELISA
(Cayman Chemical).
Generation of the TRE-shRNA transgenic mouse
Animal experiments were conducted according to guidelines of
the UCLA Animal Care Committee and the Cold Spring Harbor
Laboratory Animal Facility. Protocols were subject to ethical
review and approval by the UCLA Animal Research Committee
(Protocol No. 2010-074-01). Mice were generated using the Flp/
FRT recombinase-mediated cassette exchange (RMCE) strategy,
using ‘KH2’ C57BL/6; SJL ES cells that contain an frt-hygro-pA
‘homing’ cassette downstream of the ColA1 gene on mouse
chromosome 11 [22–24]. Site-specific integration into the homing
Reversible Regulation of COX-2 Expression by RNAi in Mice
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cassette is achieved by FLPe recombinase-mediated recombination
between the FRT-sites in the ColA1 locus on chromosome 11 and
in the targeting vector. The targeting vector, pCol-TGM, contains
a GFP open reading frame immediately downstream of the TRE
promoter, followed by the miR30-based shRNA expression
cassette. The Cox2.2058 shRNA in the LMP shRNA expression
cassette was cloned into the miR30 backbone of this targeting
vector at the single XhoI/EcoRI site. The pCol-TGM targeting
vector containing the Cox2.2058 shRNA and a plasmid expressing
Flpe-recombinase (pCAGs-Flpe) were then co-electroporated into
KH2 ES cells. Flpe-mediated recombination confers hygromycin
resistance. Sequencing confirmed Cox2.2058 shRNA in Hygro-
mycin-resistant ESC clones. Transgenic mice were then generated
using tetraploid embryo complementation, to give rise to mice that
are derived directly from the targeted ES cells [25–27].
To elicit doxycycline (DOX) inducible expression from the TRE
promoter we used the CAGGs-rtTA3 (4288) transactivator mouse
line [24], which expresses rtTA3 from the chicken beta-actin/
CMV (CAGGs) promoter. CAGGs-rtTA3 (termed ‘‘CAG-rtTA3’’
or ‘‘C3’’) and TG-Cox2.2058 (termed ‘‘shCox-2’’) mice were
crossed to produce double transgenic TG-Cox2.2058/CAG-
rtTA3 (shCox2/C3) mice. Offspring were genotyped by genomic
DNA PCR for the shCox2 [ColArev45 primer [20] and shCox2
forward primer: 59-AAA GGA CAA ACA CCG GAT GC-39] and
C3 alleles [24]. To guarantee that all shCox2/C3 mice carry only
a single copy of the shCox2 or C3 transgenes, mouse strains were
maintained separately and only crossed when generating double
transgenic mice.
Figure 1. Identifying small inhibitory RNAs for COX-2. (A) Schematic representation of the Cox2 transcript, indicating target areas of four
designed shRNAs. The COX-2 protein-coding region is indicated as a filled box, 59 and 39 untranslated mRNA as solid lines. Four 22-nucleotide shRNAs
for Cox2 were designed; (1) Cox2.284, (2) Cox2.1082, (3) Cox2.2058 and (4) Cox2.3711, the number reflecting the first nucleotide position of the target
sequence in the mRNA transcript. The shRNA sequences were then converted into cloning templates and ligated into the LMP retrovirus vector. This
vector contains an XhoI/EcoR1 cloning site for shRNAs within a miR30 backbone (shRNAmir). The LMP construct is shown as it appears after
integration; shRNAs are constitutively expressed from the 59LTR promoter. The LMP retrovirus also encodes a puromycin-resistance gene for selection
and GFP as a fluorescent marker. (B) NIH3T3 cells were transduced at a low MOI with each of the four LMP vectors containing miR30-based shRNAs
that target the Cox2 transcript, or with a control luciferase-targeted shRNA. Retrovirus-transduced cells were selected for integrated provirus by
culturing in puromycin. Puromycin-selected cell populations were shifted overnight to 1% serum, then treated with 20% serum for 6 hours. Cell
extracts were immunoblotted for COX-2 and GAPDH. (C) RAW264.7 cells stably transduced either with the luciferase shRNA LMP vector or with the
LMP vector encoding Cox2-targeted Cox2.2058 shRNA were stimulated with LPS (50 ng/mL) or with saline for four hours. Cell extracts were prepared
and analyzed for COX-2 protein and GAPDH. The quantified COX-2 signal was normalized against GAPDH. (D) PGE2 accumulation in the media of
serum-stimulated NIH3T3 cells expressing shRNA Cox2.2058 or the control luciferase shRNA. NIH3T3 cells expressing the two shRNAs were shifted
from media containing 1% FBS to 20% FBS and, at times shown, media samples were assayed for PGE2 levels.
doi:10.1371/journal.pone.0101263.g001
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Generation of a targeted luciferase knockin mouse with
the Cox2 39untranslated region (39UTR)
We followed a procedure similar to that used in the construction
of the Cox2fluc knockin allele, in which the firefly luciferase (ffLuc)
coding region and an SV40 39UTR are substituted for the COX-2
coding region and 39UTR [28]. The targeting vector contains a
6.7 kb genomic region upstream of the Cox2 ATG initiation
codon, the firefly luciferase coding region placed at the Cox2 gene
initiating ATG codon, a floxed neo cassette for positive selection, a
1 kb genomic region downstream of the Cox2 termination codon,
and the diphtheria toxin cassette for negative selection (Fig. 2A).
This plasmid was generated by recombineering, using pCOXLuc-
DT created previously [28], which contains the 59 Cox2 genomic
region and the ffLuc gene, and pCOXlucNeofloxedCOX3UTRDT
which contains the remaining elements described above. The final
targeting vector was confirmed by DNA sequencing. To generate
Cox2 knockin mice, the targeting vector was linearized by NotI
digestion and electroporated into LW1 embryonic stem (ES) cells.
ESC clones containing the Cox2luc-floxed-neo allele were screened by
PCR using the primer pair PGKRa (59-CTAAAGCG-
CATGCTCCAGACT-39 targeting the PGK promoter) and
NeoPCR-REV (59-TAAAGTGACCACGAGAAACGGA-39 tar-
geting the neoB gene). Homologous recombination was verified by
Southern blotting using a 175 bp SacI/ApaI fragment within the
Cox2 59-UTR to probe the PvuII/NheI-digested mouse genomic
DNA. ESC clones were injected into C57BL/6 blastocysts to
generate chimeric mice. One germline transmission founder was
obtained. This mouse was crossed with a Cre transgenic mouse to
generate Cox2 heterozygous mice. Complete excision of the floxed
neo cassette was confirmed by PCR (Luc-F4 59-GCT GGG CGT
TAA TCA GAG AG-39, Lox-R2 59-CCA AGC TAT CGA ATT
CCT GC-39) and Southern blot. The targeted Cox2 allele is
referred to as Cox2tm2Luc (‘Cox2 targeted mutation 2 Luciferase’) or
‘Luc’.
The Cox2tm2Luc allele was detected in cells and in mice by PCR:
Luc1 primer, 59-CCA GGG ATT TCA GTC GAT GT-39 and
Luc2 primer; 59-CGC AGT ATC CGG AAT GAT TT-39). Cox2
wild type primers: CoxF1, 59-AAT TAC TGC TGA AGC CCA
CC-39; E4R2: 59-AGA AGG CTT CCC AGC TTT TGT AAC
C-39.
Isolation and culture of mouse primary bone marrow
macrophages and fibroblasts
Macrophages. Bone marrow macrophages were isolated
from the tibia, femur and pelvis, using standard procedures. Cells
were washed, depleted of red blood cells, plated into RPMI 1640
medium (Gibco/Invitrogen) supplemented with 10% FBS, 1%
Penicillin/Streptomycin, 10 mM Hepes and 0.01 mg/mL mouse
macrophage colony stimulating factor (M-CSF, Gibco/Invitro-
gen), and cultured for 5 days at 37uC in 10% CO2. All
experiments were performed in the following three days. For
Cox2 gene activation, cells were treated with LPS (50 ng/mL) for 4
hours in the presence or absence of DOX (Clontech), as described
in Results and Figure Legends.
Fibroblasts. Primary lung and skin fibroblasts were isolated
as previously described [29]. Tissues were collected, cut into small
pieces, treated with liberase (Roche) for 60 minutes, and then
cultured at 37uC in 5% CO2 for 5 days in DMEM/F12 medium
(Gibco/Invitrogen) supplemented with 15% FBS and 1% Penicil-
lin/Streptomycin, to allow fibroblasts to migrate from the
fragments. Remaining tissue pieces were removed and the
medium was changed to EMEM (Gibco/Invitrogen) supplement-
ed with 15% FBS, 1% Penicillin/Streptomycin, non-essential
amino acids and sodium pyruvate. COX-2 and luciferase
expression was induced and analyzed as described above for
retrovirus transduced NIH3T3 cells. DOX was added to the
media at times, concentrations and durations indicated in Results
and Figure Legends. DOX was changed daily.
Cox2 gene activation in vivo
Cox2 gene activation by systemic interferon gamma and
endotoxin. Systemic Cox2 activation by IFN-c and LPS for
triple transgenic shCox2/C3/Luc+ mice was performed as
described previously [28]. Control mice were injected with saline.
Six hours after LPS injection the mice were euthanized. Tissues
were rapidly removed, placed in culture dishes and used for
luciferase-dependent bioluminescence imaging. The tissues were
then snap-frozen, and used subsequently for in vitro luciferase
enzyme activity quantification and for COX-2 Western blotting.
Cox2 gene activation in the mouse paw by
zymosan. Triple transgenic shCox2/C3/Luc+ mice were fed
a DOX-free diet or a DOX (625 mg/kg)-containing diet (Harlan
Tek) for 12 days. Inflammation was induced by sub-plantar
Zymosan injection into the left hind paw, as described previously
[28]. Saline injection into the right hind paw was used as a control.
At the indicated time points mice were anesthetized with
isoflurane and imaged non-invasively for GFP-dependent fluores-
cence as surrogate for shRNA expression and for luciferase-
dependent bioluminescence.
Cox2 gene activation in skin by 12-O-
tetradecanoylphorbol-13-acetate (TPA). Mice were anesthe-
tized briefly by isoflurane inhalation. A small area of the dorsal
skin was exposed by shaving and TPA (LC Laboratories, 5 mg in
acetone) was applied. Twenty-four hours later mice were imaged
non-invasively for GFP-dependent fluorescence to analyze shCox2
expression and for luciferase-dependent bioluminescence. Alter-
natively, mice were euthanized and skin was collected and
processed for Western blotting.
Bioluminescence and fluorescence imaging
For bioluminescence in vivo imaging, mice were anesthetized
with isoflurane, shaved if applicable, injected i.p. with D-luciferin
(125 mg/kg) and placed into the imaging chamber of an IVIS
imaging system (Xenogen). For ex vivo tissue imaging, mice were
euthanized and tissues were rapidly excised, placed on culture
dishes, covered with D-luciferin (15 mg/mL) solution and imaged.
Bioluminescence emissions were collected over 3 minute periods
at 5-minute intervals. Whole body and ex vivo tissue images were
acquired repeatedly until the maximum peak of photon number
was confirmed during the 3 minute scans. Data at the 3-minute
time point that gave the highest photon number were used for
further analysis, using Living Image software (Perkin Elmer). For
bioluminescence quantification, a region of interest (ROI) was
drawn manually and bioluminescence was recorded as radiance
(peak photon/sec/cm2/sr).
In vivo fluorescent images were obtained at 465 nm excitation
and 520 nm emission wavelengths. Fluorescence was quantified by
drawing ROIs and displayed as mean fluorescent intensity.
Luciferase activity assays
Cultured cells and tissues were washed with PBS and
homogenized in Passive Lysis Buffer (Promega). Debris was
removed by centrifugation and luciferase activity was determined
in extracts, using the Luciferase Assay System (Promega) and
Luminat LB9501 instrumentation. Luciferase activity in cell/tissue
extracts was normalized to protein content determined by
Reversible Regulation of COX-2 Expression by RNAi in Mice
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Bradford assay, and displayed as relative light units per mg protein
(RLU/mg).
Western blotting
The following antibodies were used for Western blotting: GFP,
rabbit polyclonal IgG, Abcam, ab290, 1:2000; glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), rabbit polyclonal IgG, Santa
Cruz, sc-25778, 1:1000; COX-2 (in skin), rabbit polyclonal IgG,
Cayman, 160106, 1:100; COX-2 (all other tissues and cells), rabbit
polyclonal IgG, Santa Cruz, sc-1747-R, 1:1000. Extracts of cells or
tissues that were previously lysed in Passive Lysis Buffer were
mixed with SDS sample buffer and boiled prior to separation on
SDS-PAGE gels. For Western blot analysis of skin, tissue was
homogenized in RIPA buffer containing a proteinase inhibitor
cocktail (Santa Cruz, sc-24948), sonicated and incubated at 4uC
for 20 minutes on a rocking platform. Cell debris was removed by
centrifugation and protein content was determined by Bradford
assay.
Proteins (40–80 mg) were separated on 10% SDS-PAGE gels
and transferred onto nitrocellulose membranes. The membranes
were blocked with 4% milk protein in PBS/0.1% Tween-20,
probed with primary antibodies in the same buffer over night at
4uC, then incubated with anti-rabbit HRP-conjugated secondary
antibody (Santa Cruz, sc-2004, 1:5000) for one hour at room
temperature. Proteins were visualized on autoradiographic film
using ECL reagent (Pierce). For quantification, membranes were
scanned with Typhoon instrumentation. Results were graphed as
volume densities relative to the GAPDH signal.
Figure 2. Construction of Cox2tm2Luc/+, a mouse strain in which firefly luciferase replaces the Cox2 coding region. (A) Schematic
representation of the wild-type Cox2 allele and the targeting strategy to create the Cox2tm2Luc knockin allele. The firefly luciferase coding region
(ffLuc), PGK-neo (neo) selection cassette, and PGK-DT (DT) selection cassette in the targeting vector are shown as open boxes. Grey triangles depict
loxP sites. Homologous recombination was confirmed by PCR (black arrows) and Southern blot analysis in ES cells. The neomycin-resistance cassette
was deleted by Cre recombinase expression, resulting in the ‘neo-deleted’ allele. Deletion was confirmed by PCR (grey arrows). Cox2 gene sequences
are replaced by the firefly luciferase coding region between the ATG translational start site located at the end of exon 1 (e1) and the TAA Cox2 stop
codon located on exon 10. There are no modifications of the untranslated 59UTR and 39UTR either upstream of the ATG or downstream from the TAA.
(B) Unstimulated luciferase activity in isolated Cox2tm2Luc/+ tissues. Luciferase activity was quantified by ex vivo bioluminescent imaging. Data are
means +/2 SD (n = 4). (C) COX-2 and luciferase induction in primary cells isolated from Cox2tm2Luc/+ mice. Bone marrow macrophage cultures were
stimulated with LPS (50 ng/mL) for four hours. Lung fibroblast cultures were stimulated with 20% serum for six hours. Cell extracts were analyzed for
luciferase enzymatic activity and COX-2 protein. Luciferase activity is displayed as relative light units (RLU) per microgram protein. Data are means
+/2 SD (**, p,0.01, ***, p,0.001, n = 3). (D) Interferon gamma and endotoxin (IFNc/LPS) COX-2 and luciferase induction in the spleens of
heterozygous Cox2tm2Luc/+ mice. Four mice were injected i.p. with IFNc, (1 mg/mouse) and two hours later with LPS (3 mg/kg) or saline. After 6 hours,
mice were euthanized, spleens were excised and luciferase bioluminescence was quantified by bioluminescent imaging (left panel). Luciferase
enzymatic activity and COX-2 protein levels were measured in extracts (right panel). Data are means +/2 SD (**, p,0.01).
doi:10.1371/journal.pone.0101263.g002
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Histology and immunohistochemical staining
For immunohistochemistry of COX-2 and GFP, skin samples
were fixed overnight in 10% buffered formalin, then embedded in
paraffin. Skin sections (5 mm) were de-paraffinated and treated for
antigen retrieval with the citrate buffer heat method. Endogenous
peroxidases were quenched with 3% hydrogen peroxide and
sections were blocked in 5% normal donkey serum/PBS for one
hour before overnight incubation with rabbit anti-COX-2
antibody (1:25; Cayman, 160106) or rabbit anti-GFP antibody
(1:5000; Abcam, ab290) at 4uC. Slides were washed and incubated
with biotin-labeled goat anti-rabbit secondary antibody (1:250;
Jackson Laboratories). Signal was developed using the ABC and
DAB vector kits (Vector Laboratories). Sections were counter-
stained with hematoxylin.
To measure leukocyte infiltration, sections were stained with
hematoxylin and eosin and the numbers of infiltrating leukocytes
were counted in six fields per section in a blinded fashion. Images
were obtained with an inverted microscope (Nikon, Eclipse 2000
TE) using NIS Elements imaging software.
Statistics
Data are expressed as means +/2 S.D. (standard deviation).
Data were compared between groups with the unpaired Student’s
t test or one-way analysis of variance as appropriate. p values less
than 0.05 were considered significant. All experiments were
performed a minimum of three times with a minimum of triplicate
samples.
Results
Identifying small hairpin RNAs that can block COX-2
expression
Using improved prediction methods for the design of miR30-
based shRNAs [20], we identified four 22-mer guide strand
sequences; Cox2.284 (1), Cox2.1082 (2), Cox2.2058 (3) and
Cox2.3711 (4) (Fig. 1A), complementary to the Cox2 coding region
(1 and 2) or the Cox2 39-UTR sequence (3 and 4). Guide and
complementary sense strand sequences, were embedded into
cloning templates as described [20]. Appropriate products
carrying the XhoI/EcoRI restriction sites at their ends and
comprising the common and Cox2-specific stem sequences and
the 19 bp loop were used to create miR30-adapted shRNAs.
Since shRNA transgenic mice will harbor only one copy of the
shRNA expression cassette, it is necessary to identify shRNAs that
efficiently silence COX-2 expression when expressed from a single
genomic locus. To identify appropriate shRNAs, each cloning
template containing a COX-2 shRNA sequence was ligated into
LMP, a retroviral miR30-shRNA expression vector in which
miRNA-based shRNA (shRNAmir) expression is driven from the
viral 59LTR promoter (Fig. 1A). The vector also contains a PGK
promoter-driven puromycin resistance gene and a green fluores-
cence protein (GFP) gene to select and identify transduced cells
(Fig. 1A, lower illustration).
To test the candidate shRNAs for suppression of COX-2
expression when expressed from a single gene copy, NIH3T3 cells
were transduced with the four LMP vectors at a very low
multiplicity of infection (MOI). Flow cytometry of the transduced
cell populations demonstrated that only ,1% of the cells
expressed GFP (Supplementary Fig. 1A), suggesting transduced
cells contained only a single viral genome. Subsequent puromycin
selection ensured expansion only of transduced cells, resulting in a
mixed cell population of single integrants. Southern blot analysis
(Fig. S1B–D) confirmed multiple integration sites in retrovirus
transduced, antibiotic-selected cell populations.
The Cox2 gene can be induced in NIH3T3 cells by increasing
the serum concentration in the medium. The abilities of the four
Cox2 specific shRNAs to block COX-2 protein expression were
examined by stimulating the four retrovirus-transduced NIH3T3
cell populations with medium containing 20% serum for six hours,
then analyzing cell extracts for COX-2 protein content (Fig. 1B).
As expected, cells transduced with a vector encoding a control
shRNA against luciferase demonstrated substantial COX-2
protein induction. Cells transduced with COX-2 shRNAs 1 and
2 also expressed substantial COX-2 protein in response to 20%
serum; these shRNAs did not have a significant effect on COX-2
expression at single-copy conditions. In contrast, cells transduced
with COX-2 shRNAs 3 and 4 expressed only small amounts of
COX-2 protein in response to serum stimulation. We chose COX-
2 shRNA 3 (Cox2.2058) for further studies, as its target location in
the mRNA should make it effective in silencing COX-2 expression
from both the short and long Cox2 gene transcripts [30].
To confirm COX-2 knockdown by Cox2.2058 in a different cell
type, LMP vector transduction and puromycin selection were
repeated in RAW264.7 cells, a murine monocyte cell line.
RAW264.7 cells transduced with the control luciferase shRNA
vector express substantial COX-2 protein in response to bacterial
lipopolysaccharide (LPS, 50 ng/mL), compared to saline-treated
cells (Fig. 1C). In contrast, RAW264.7 cells transduced with
Cox2.2058 did not express COX-2 protein above baseline values
when treated with LPS. Western blot data quantification indicated
over 90% reduction of LPS-induced COX-2 expression (Fig. 1C).
To demonstrate functional inactivation of the Cox2 transcript by
Cox2.2058, prostaglandin E2 (PGE2) production was examined in
serum-stimulated NIH3T3 cells expressing either the control
luciferase shRNA or Cox2.2058. Serum-stimulated cells express-
ing the control shRNA secrete continuously increasing amounts of
PGE2 into the culture medium (Fig. 1D). In contrast, Cox2-
targeted Cox2.2058 expression completely eliminated serum-
induced PGE2 accumulation. In summary, shRNA 3
(Cox2.2058) was highly effective in suppressing COX-2 expression
and activity when expressed at a single copy per cell.
A reporter mouse in which the endogenous Cox2 coding
region is replaced with the firefly luciferase coding
region. To test the effects of the COX-2 shRNA Cox2.2058
on COX-2 expression it would be useful to have a reporter system
that could be non-invasively and repeatedly monitored in
individual mice. We previously constructed a knock-in mouse,
Cox2fLuc/+, in which firefly luciferase is expressed from the
endogenous Cox2 gene [28], and have used this mouse to monitor
expression from the Cox2 gene in a variety of contexts [28,31–33].
However, the Cox2fLuc allele contains an SV40 39UTR substituted
for the endogenous Cox2 39UTR. Because Cox2.2058 targets the
39UTR of the Cox2 mRNA, we constructed a new knock-in mouse
in which the luciferase coding region is also driven by the
endogenous Cox2 promoter, but in which the luciferase coding
sequence is followed by the endogenous Cox2 39UTR. Using this
mouse, the efficacy of shRNA-mediated Cox2 knockdown, and its
reversibility can be evaluated by noninvasive imaging of Cox2
promoter-driven luciferase activity.
We employed a knockin strategy whereby the firefly luciferase
(ffluc) coding region and a PGK-neomycin selection cassette in the
targeting vector were inserted into the Cox2 locus by homologous
recombination in ES cells (Fig. 2A). Immediately downstream
from the neo selection cassette for selection of ES cells containing
the targeted allele, the targeting vector contains the Cox2
translational stop codon (TAA), followed by the Cox2 gene
39UTR of exon ten and a diphtheria toxin cassette. After selection
of ES cells containing the targeted allele, the neo selection cassette
Reversible Regulation of COX-2 Expression by RNAi in Mice
PLOS ONE | www.plosone.org 6 July 2014 | Volume 9 | Issue 7 | e101263
was excised by transient Cre expression, resulting in the final neo-
deleted, ffLuc-expressing allele. This second Cox2-targeted firefly
luciferase knock-in allele was termed ‘targeted mutation 2
luciferase’ (tm2Luc).
To characterize Cox2tm2Luc/+ mice we first determined which
organs demonstrate detectable luciferase gene expression in
untreated mice. Luciferase expression was examined by biolumi-
nescent imaging of tissues dissected from Cox2tm2Luc/+ mice, and
quantified from the optical imaging data. The highest constitutive
luciferase expression from the Cox2 gene occurred in the vas
deferens (Fig. 2B, right panel), consistent with what has been
reported previously [34]. Substantial luciferase expression was also
observed in the brain, throughout the gastrointestinal tract, in the
thymus, and to lesser extent in stomach, skin and lungs (Fig. 2B,
left panel). Luciferase activity was low or undetectable in all other
organs examined, including pancreas, kidney, liver, spleen, and
heart. The luciferase expression pattern confirms published results
for COX-2 expression obtained by immunohistochemistry and
Western blotting, and by our previous results with the Cox2fLuc/+
mouse [28,31,34,35].
To further characterize luciferase and COX-2 expression in
tissues from heterozygous Cox2tm2Luc/+ mice, bone marrow
macrophages and lung fibroblasts from mice were harvested,
cultured and appropriately stimulated to induce Cox2 expression.
Cell extracts were assayed both for luciferase enzymatic activity
and for COX-2 protein (Fig. 2C). LPS (50 ng/mL)-treated
macrophages showed parallel increases in luciferase activity and
COX-2 protein expression. Serum-stimulated lung fibroblasts also
showed similar concomitant luciferase enzymatic activity and
COX-2 protein accumulation.
Figure 3. Inducible COX-2 shRNA expression suppresses Cox2-driven gene expression in cells cultured from triple transgenic mice.
(A) Upper panel: The diagram shows the pCol-TGM targeting construct encoding GFP and COX-2 shRNA, expressed from a TRE promoter. Co-
electroporation, with pCAGS-Flpe recombinase, into KH2 ES cells results in integration of the construct into the ColA1 locus. ShCox2 mice are crossed
with tet-transactivator mice (CAG-rtTA3/C3) to create double trangenics. Lower panel; in triple transgenic shCox2/C3/Luc+ mice, DOX-rtTA3 activates
the TRE promoter, driving GFP and shCox2 expression; shCox2 blocks COX-2 and luciferase expression. Without DOX the TRE promoter is quiescent;
COX-2 and luciferase are expressed normally. (B) Inducible suppression of Cox2 gene expression in fibroblasts. Skin fibroblasts from triple transgenic
shCox2/C3/Luc+ and Luc+ mice were cultured for four days in the absence or presence of DOX (1 mg/mL), shifted to 1% serum overnight, then
stimulated with 20% serum for 6 hours. Luciferase activity was measured in extracts, COX-2 and GFP protein were analyzed by Western blot.
Luciferase activity was normalized to protein content. (C) Reversible suppression of Cox2 gene expression in skin fibroblasts. Cells were untreated (no
DOX), treated for 4 days with DOX (D4 DOX), or treated for 4 days with DOX followed by 4 days without DOX (D4 DOX, D4 no DOX). Cells were
stimulated with medium containing 20% FBS; luciferase activity, COX-2 expression and GFP expression were analyzed. (D) Bone marrow
macrophages from shCox2/C3/Luc+ and control Luc+ mice were cultured in the indicated concentrations of DOX overnight, then stimulated for 4
hours with LPS (50 ng/mL) to induce COX-2. Cell extracts were analyzed for luciferase activity and COX-2 protein. Luciferase activities are normalized
to LPS stimulation in the absence of DOX. Data are means +/2 SD. Statistics compare DOX-treated cultures with cells not receiving DOX (*, p,0.05;
**, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0101263.g003
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The final set of experiments validating the Cox2tm2Luc/+ mouse
evaluated coordinated luciferase and COX-2 expression in vivo.
Systemic interferon gamma (IFN-c) and endotoxin (LPS) injection
induces robust COX-2 induction in spleen, lung, heart and liver
[28]. Cox2tm2Luc/+ mice were injected first with IFNc 1 mg/mouse),
and two hours later with LPS (3 mg/kg). Six hours after LPS
injection organs were removed, exposed to luciferin substrate, and
imaged to measure bioluminescence. Substantially enhanced
bioluminescence was observed in spleen, liver, heart and lung
tissues of [IFN-c + LPS] injected Cox2tm2Luc/+ mice, compared to
saline injected control mice (Fig. 2D, left panel and Fig. S2). After
imaging, tissues were homogenized and extracts were analyzed
both for luciferase enzymatic activity and for COX-2 expression
(Fig. 2D, right panel and Fig. S2). IFN-c+LPS induced both
luciferase and COX-2 protein in the tissues examined; demon-
strating luciferase induction from the Cox2tm2Luc allele can be used
to determine COX-2 expression in heterozygous Cox2tm2Luc/+
mice.
Generation of a tetracycline-inducible short hairpin RNA
for COX-2 inhibition in mice. To develop a single-copy
transgenic mouse in which Cox2.2058 can be expressed in an
inducible and reversible manner, we subcloned the Cox2.2058
sequence into the targeting vector (pCol-TGM, [24]) (Fig. 3A,
upper panel). pCol-TGM contains a miR30-based expression
cassette regulated by an inducible tetracycline response element
(TRE) promoter. The pCol-TGM vector also contains, between
the TRE promoter and the shRNA cloning site, a GFP coding
region, which both enhances knockdown of target genes and
enables easy tracking and isolation of shRNA-expressing cells [24].
Transgenic mice were generated using the Flp/FRT recombinase
mediated cassette exchange (RMCE) strategy [22] to target the
Cox2.2058 containing pCol-TGM sequence into the frt-hygro-pA
‘homing’ cassette of KH2 ES cells [20,23,24]. Fig. 3A (upper
panel) shows the targeting vector (pCol-TGM) and the integrated
construct after homologous recombination to create the TG-
Cox2.2058 transgene allele. After selection and confirmation of ES
cell clones with correct shRNA sequence, transgenic mice were
generated using tetraploid embryo complementation [25–27].
Triple transgenic mice containing the CAG-rtTA3 (C3)
reverse transactivator, the TG-Cox2. 2058 shRNA
(shCox2) and the Cox2tm2Luc allele (Luc+) knockin. The
TRE promoter in TG-Cox2.2058 (shCox2) transgenic mice is
activated only in the presence of a tetracycline-regulatable
transactivator. We crossed the shCox2 mice to the CAG-rtTA3
(C3) reverse transactivator mouse line. The CAG promoter is
particularly well expressed in skin epidermis [24]. Moreover,
quantification of luciferase expression in vivo by non-invasive
bioluminescent imaging is most sensitive and efficient in skin
[36]. Consequently, to analyze the ability of shCox2 to reversibly
suppress COX-2 expression we crossed Cox2tm2Luc/+ (Luc+)
reporter mice to the shCox2/C3 double transgenic mouse line.
Triple transgenic mice carrying the CAG-rtTA3 transactivator
(C3), the Cox2.2058 shRNA transgene (shCox2) and the Cox2tm2Luc
allele (Luc+) develop normally. In subsequent experiments their
luciferase expression is compared with single transgene heterozy-
gous Cox2tm2Luc/+ (Luc+) littermate controls.
Tet-regulated COX-2-shRNA reversibly suppresses
expression from the Cox2 gene in cultured cells. CAG-
rtTA3 is a ‘tet-on’ transactivator, inactive unless a tetracycline
analog such as doxycycline (DOX) is present. In the presence of
DOX, rtTA3 should activate the TRE promoter, leading to
shCox2 expression and subsequent down-regulation of Cox2
transcripts that contain the targeted Cox2 gene 39UTR sequence
(Fig. 3A lower panel). DOX withdrawal should inactivate the
rtTA3 transactivator, and TRE-mediated transcription should
cease.
CAG-rtTa3 driven gene expression is high in mouse skin [24].
We established primary skin fibroblast cultures both from triple
transgenic shCox2/C3/Luc+ mice and from Luc+ control mice,
to test DOX-regulated Cox2 gene silencing. To examine whether
DOX-induced shCox2 expression results in reduced expression
from the Cox2 gene locus, primary shCox2/C3/Luc+ skin
fibroblasts and fibroblasts from Luc+ mice, cultured either in the
presence or absence of DOX, were stimulated with 20% FBS, and
assayed for luciferase activity. Skin fibroblasts from both mouse
strains cultured in the absence of DOX demonstrate a substantial
increase in FBS-stimulated luciferase activity in cell extracts over
unstimulated cells (Fig. 3B). DOX reduced luciferase production in
FBS-treated triple transgenic fibroblasts by ,75% (Fig. 3B, left
panel). COX-2 induction in FBS-stimulated triple transgenic
fibroblasts was also substantially reduced in the presence of DOX
(Fig. 3B, left panel). GFP expression in triple transgenic fibroblasts
was observed only in DOX-treated cells, indicating that shCox2
production was DOX-dependent (Fig. 3B, Western blot). In
contrast to results for fibroblasts from the triple transgenic cells,
both luciferase activity and COX-2 protein expression in Luc+
cells were unaffected by DOX, ruling out non-specific side effects
by DOX treatment (Fig. 3B, right panels).
To test the reversibility of DOX-dependent, shCox2-regulated
COX-2 knockdown, fibroblasts from triple transgenic shCox2/
C3/Luc+ and Luc+ mice were divided into three treatment
groups. Cells were either treated with DOX for four days (D4
DOX), treated with DOX for 4 days followed by 4 days without
DOX (D4 DOX, D4 no DOX) or never treated with DOX (no
DOX). Cells were then treated with 20% FBS. DOX treatment
(D4 DOX) resulted in significant reduction of luciferase and
COX-2 expression in response to FBS stimulation in cells from
triple transgenic (shCox2/C3/Luc+) mice, but not in FBS-
stimulated cells from Luc+ mice (Fig. 3C). Moreover, FBS-
stimulated luciferase activity and COX-2 protein expression
following DOX withdrawal (D4 DOX, D4 no DOX), were
identical to that observed in cells that were never exposed to DOX
(no DOX), demonstrating that the DOX-regulated, shCox2-
dependent inhibition of COX-2 expression and luciferase activity
were fully reversible. GFP expression correlated strongly, in
reciprocal fashion, with Cox2 gene knockdown (Fig. 3C, upper
right panel), confirming its role as a reliable biomarker of shCox2
expression.
Luciferase and COX-2 were strongly induced by LPS in
primary bone marrow macrophages from both triple transgenic
and Luc+ mice (Fig. 3D). Macrophages from both mouse strains
were cultured overnight with increasing DOX concentrations,
then stimulated with LPS. We observed dose-dependent reduc-
tions in luciferase activity and COX-2 expression in shCox2/C3/
Luc+ macrophages, but not in Luc+ macrophages. These
experiments demonstrate that co-expression of CAG-rtTA3 (C3)
and TG-Cox2.2058 (shCox2) results in DOX-dependent, revers-
ible inhibition of Cox2 gene expression.
Doxycycline-regulated shCox2 expression suppresses
Cox2 gene expression in zymosan-induced inflammation
in the mouse paw. Zymosan-induced paw inflammation in
rodents is a classic localized inflammation model [37,38]. We
previously demonstrated that zymosan inflammation is accompa-
nied by a robust, self-resolving COX-2 induction [28] that can be
measured by repeated non-invasive optical imaging in the
Cox2fLuc/+mouse [28]. Consequently, the paw inflammation model
should also be very useful for initial characterization of the triple
transgenic shCox2/C3/Luc+ mouse.
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To determine the dynamics of DOX-induced, shCox2-mediat-
ed, longitudinal silencing of the Cox2 gene, three triple transgenic
shCox2/C3/Luc+ mice received a DOX-containing diet for 12
days, while three additional triple transgenic mice were fed a
control DOX-free diet. To analyze whether the shCox2 shRNA
was expressed, and to obtain luciferase activity levels at baseline,
the mice were imaged non-invasively for GFP fluorescence and for
luciferase-dependent bioluminescent activity prior to zymosan
administration (Fig. 4A and 4B, 0 time point). GFP fluorescence
from the paws of mice that received the DOX-containing diet (+
DOX) was greater than 10-fold increased when compared to paws
of mice that did not receive DOX, indicating that shCox2
expression was strongly induced by DOX (Fig. 4A).
A 2% zymosan suspension in saline (30 mL) was then injected
sub-plantar into the left rear paws of all six shCox2/C3/Luc+
mice, and saline was injected into the right rear (contralateral)
paws. Luciferase expression from the Cox2tm2Luc allele was
measured by bioluminescence imaging at 6, 12, and 24 hours
post zymosan injection (Fig. 4B). Zymosan injection resulted in
rapid luciferase accumulation compared to luciferase activity at
baseline, prior to zymosan injections; zymosan-induced luciferase
activity peaked between 6 and 12 hours, then decreased to near-
baseline values within 24 hours (Fig. 4B). Cox2 gene-directed
luciferase activity was significantly higher throughout the induc-
tion period in mice that received a DOX-free diet (no DOX)
compared with mice fed a DOX-containing diet. Thus DOX
pretreatment resulted in significant inhibition of Cox2 gene-driven
luciferase expression during zymosan-induced paw inflammation.
Zymosan-induced luciferase activity in Luc+ control mice fed a
DOX-containing diet was not significantly different from lucifer-
ase activity observed in shCox2/C3/Luc+ mice on a DOX-free
diet, confirming that the reduction in luciferase activity observed
in shCox2/C3/Luc+ mice on DOX was not simply due to the
presence of DOX (Fig. S3A).
Doxycycline-regulated shCox2 reversibly suppresses
Cox2 gene expression in TPA-treated mouse skin. Topical
TPA administration induces an inflammatory reaction in mouse
skin [39–42]. We used repeated TPA skin treatment of shCox2/
C3/Luc+ triple transgenic mice, in combination with repeated
noninvasive imaging, to evaluate reversible inactivation of Cox2-
driven luciferase expression by DOX-inducible shCox2 expression
in individual mice.
Three triple transgenic shCox2/C3/Luc+ mice and two control
Luc+ littermate control mice received a DOX-containing diet for
12 days. A small area on the back of the mice was shaved and
expression from the Cox2 gene was induced by applying TPA.
Twenty-four hours later GFP, as a measure of shCox2 expression,
and luciferase activity were measured by respective non-invasive
optical fluorescent and bioluminescent imaging (Figs. 5A and B,
top rows). After imaging, the DOX diet was replaced with a DOX-
free diet. Twelve days later mice were again subjected to TPA
treatment on their back and again imaged 24 hours later for GFP
and luciferase expression (Figs. 5A and B, middle rows). After
imaging, the mice were switched back to a DOX-containing diet
for 12 days, treated again with TPA, and imaged a third time for
DOX-mediated GFP and Cox2 gene-mediated luciferase expres-
sion (Fig. 5A and B, third rows) to determine whether Cox2
shRNA-mediated knockdown of Cox2 gene-driven transcripts is
reversible.
DOX induced a,10-fold GFP fluorescence induction in skin of
triple transgenic shCox2/C3/Luc+ mice when compared to
fluorescence from Luc+ control mice, which do not contain the
GFP-linked shRNA transgene (Fig. 5A, +DOX, top row). Twelve
days after the DOX diet was replaced with a DOX-free diet, skin
GFP expression returned to baseline (Fig. 5A, middle row),
suggesting that the COX-2-shRNA is no longer expressed. When
shCox2/C3/Luc+ mice were returned to a DOX-containing diet
for 12 days, they again showed a ,10-fold induction of GFP
expression (Fig. 5A, bottom row). These data demonstrate that
shCox2 expression can be reversibly up-and-down-regulated
within the same mouse, in response to the presence or absence
of DOX in the diet.
Figure 4. DOX-dependent suppression of Cox2 driven lucifer-
ase expression in triple transgenic mice during zymosan-
induced paw inflammation. (A) Fluorescent in vivo GFP imaging of
shCox2/C3/Luc+ triple transgenic mice fed either a control diet (no
DOX) or a DOX-containing diet (+DOX) for 12 days. GFP fluorescence
was quantified with Living Image software. Data are means +/2 SD, (n
= 3; ***, p,0.001). (B) ShCox2/C3/Luc+ mice were injected intraplan-
tarly in the left hind paw with zymosan (30 mL, 2% w/v) and with saline
in the contralateral hind paw. In vivo luciferase bioluminescence was
non-invasively and repeatedly measured and quantified at the indicated
time points. Each curve represents data from an individual animal. To
control for individual animal variability the bioluminescence in the
contralateral control saline-infected paw was subtracted from the
bioluminescence value of the zymosan-injected paw for each observa-
tion.
doi:10.1371/journal.pone.0101263.g004
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In the presence of DOX in the diet, when DOX-dependent
TG-Cox22058 (shCox2) is strongly expressed (Fig. 5A, top row),
TPA elicited little or no Cox2 gene-driven luciferase expression in
triple transgenic shCox2/C3/Luc+ mice (Fig. 5B, top row). In
contrast, TPA painting of Luc+ mice, which do not contain the
shCox2 transgene, elicits robust luciferase expression. Luciferase
bioluminescence in shCox2/C3/Luc+ mice was reduced by
,80% relative to luciferase expression in Luc+ mice when the
mice are on a DOX-containing diet (Fig. 5B, top row). However,
when DOX is removed from the diet of shCox2/C3/Luc+ mice, a
condition under which there is no expression of DOX-dependent
shCox2, indicated by a lack of GFP expression (Fig. 5A, middle
row), TPA induced equivalent levels of Cox2 gene-dependent
luciferase expression in shCox2/C3/Luc+ mice and the control
Luc+ mice (Fig. 5B, middle row). When the shCox2/C3/Luc+
mice are returned to a DOX-containing diet (when DOX-
dependent shCox2 is once again expressed; Fig. 5A, bottom row),
TPA-induced luciferase expression is once again reduced in
shCox2/C3/Luc+ mice (by 75%) relative to luciferase expression
in Luc+ mice (Fig. 5B, bottom row). Luc+ mice on DOX-
containing and DOX-free diets expressed identical luciferase
activities in response to TPA treatment; DOX treatment alone did
not influence luciferase induction by TPA in skin (Fig. S3B).
In Fig. 5C we plot the quantification of the successive GFP/
shCox2 expression (left panel) and successive Cox2 gene-driven
luciferase expression (right panel) in shCox2/C3/Luc+ mice and
control Luc+ mice. In the presence of DOX, GFP/shCox2 is
strongly induced, both initially and again following a period of
Figure 5. Reversible DOX-dependent suppression of Cox2-driven luciferase expression in skin of TPA-treated triple transgenic mice.
Luc+ mice and triple transgenic mice were subjected to the following diet, TPA skin application and imaging schedule: Mice were placed on a DOX-
supplemented diet (+DOX) for 12 days followed by skin TPA application. Mice were imaged 24 hours later for GFP fluorescence and luciferase
bioluminescence. The mice were then shifted to a DOX-free diet (no DOX) for 12 days and the skin TPA application, GFP fluorescence and luciferase
bioluminescence analyses were repeated a second time. The mice were then shifted back to a DOX-supplemented diet (+DOX) for 12 days and the
skin TPA application, GFP fluorescence and luciferase bioluminescence analyses were repeated a third time. (A) GFP fluorescence, indicating shCox2
expression. Data are means +/2 S.D. (***p,0.001). After the DOX-diet was removed (middle panel, no DOX), GFP fluorescence returned to baseline
(p.0.05, ns). (B) Luciferase bioluminescence, indicating Cox2 gene-driven luciferase expression. TPA-induced luciferase expression is reversibly
reduced, in the presence of DOX, in triple transgenic mice. Data are means +/2 S.D (*p,0.05, ***p,0.001). (C) Summary of GFP fluorescent intensity
values (left panel) and bioluminescence (right panel) in Luc+ mice (dashed lines) and shCox2/C3/Luc+ mice (solid lines) for the three successive non-
invasive imaging analyses. Error bars show S.D.
doi:10.1371/journal.pone.0101263.g005
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DOX withdrawal; however, DOX withdrawal reduces shCox2
expression in the triple transgenic mice to the same background
level observed in Luc+ mice (Fig. 5C, left panel). The inverse is
true for Cox2 gene-driven luciferase in the triple transgenic
shCox2/C3/Luc+ mice; in the presence of DOX, when shCox2 is
expressed, luciferase expression is strongly inhibited; in the
absence of shCox2 expression (in the absence of DOX) there is
no inhibition of Cox2 gene-driven luciferase expression relative to
Luc+ mice. Repeated DOX administration once again suppresses
TPA-induced luciferase induction in the shCox2/C3/Luc+ mice.
The increasing luciferase activity observed in Luc+ mice with
successive TPA treatments (Fig. 5C, right panel, dotted line)
reflects the hyperalgesic response observed for COX-2 expression
with repeated inflammatory insult [43–46]. In summary, these
results show that shCox2 expression can be reversibly regulated
in vivo by DOX and that reversible regulation of shCox2
expression results in reciprocal downregulation of Cox2 transcripts.
Doxycycline-regulated shCox2 expression can suppress
induction of COX-2 protein and leukocyte infiltration in
mice homozygous for the wild-type Cox2
gene. Heterozygous Cox2tm2Luc/+ mice, expressing luciferase
from one allele and COX-2 protein from the other allele, are
very useful in assessing reversible and/or prolonged Cox2 gene
silencing by repeated non-invasive imaging of the same animal.
However, to employ this system to study the reversible, cell-
specific role of COX-2 in biological contexts, it is essential to
demonstrate that the single copy of the COX-2 shRNA present in
double transgenic TG-Cox2.2058/CAG-rtTA3 (shCox2/C3)
mice can, when responding to DOX, suppress COX-2 expression
in mice with two functional Cox2 alleles.
TPA treatment induced COX-2 expression in the skin of double
transgenic shCox2/C3 mice on a DOX-free diet (Fig. 6A, left
panel). In contrast, COX-2 expression was not induced above
baseline in TPA-treated double transgenic mice on the DOX-
supplemented diet, in which shCox2 was expressed (Fig. 6A, left
panel). Quantification of Western blot signals from three
independent experiments showed that the average knockdown of
COX-2 protein accumulation in the skin of DOX-treated mice
following TPA treatment was ,80–90%, corresponding to near
baseline expression (Fig. 6A, right panel).
To analyze where in the skin COX-2 expression occurs in
response to TPA treatment and to visualize the consequences of
DOX-induced shCox2 expression, COX-2 and GFP expression in
TPA-treated shCox2/C3 double transgenic mice were analyzed
by immunohistochemistry (Fig. 6B). TPA-induced COX-2 expres-
sion was visible predominantly in the basal layer of the skin
epithelium in mice on a DOX-free diet (Fig. 6B, white arrow). In
contrast, no COX-2 staining could be observed in the skin of
TPA-treated shCox2/C3 mice either on a DOX-supplemented
diet or in untreated control mice (Fig. 6B). GFP staining reflecting
shCox2 expression was visible throughout the epithelial layer in
mice that received a DOX-containing diet, but was not present in
mice on a DOX-free diet (Fig. 6B, lower panel). These
observations confirm the Western blot data, demonstrating that
single copy shCox2 expression from the DOX-activated TRE
locus is sufficient to suppress TPA-induced COX-2 expression in
skin of mice homozygous for the wild-type Cox2 gene.
Our final experiment was to demonstrate inhibition of a COX-2
dependent phenotypic function as a consequence of RNA
interference. TPA-treatment of mouse skin results in a COX-2
dependent increase in leukocyte infiltration [39]. To determine
whether shCox2-mediated suppression of TPA-induced COX-2
expression in skin results in functional COX-2 attenuation, we
analyzed the consequences of DOX treatment on leukocyte
infiltration following TPA stimulation in skin of double transgenic
shCox2/C3 mice. On a DOX-free diet, we observed an increased
number of leukocytes in the dermis of mice treated with TPA
compared to untreated control mice (36.3+/25.1 vs. 84.3+/26.9
cells per field) (Fig. 6C). In contrast, on a DOX-supplemented diet,
TPA-induced leukocyte infiltration was significantly reduced in the
dermis of TPA-treated shCox2/C3 mice compared to TPA-
treated mice on a control diet (58.9+/210.9 vs. 84.3+/26.9)
(Fig. 6C).
In summary, we have established a mouse strain that expresses a
tet-regulatable, miR30-based shRNA targeting the Cox2 transcript,
and have demonstrated reversible and functional DOX-mediated
suppression of Cox2 gene expression.
Discussion
In this report we describe the creation of a mouse model in
which COX-2 expression can be cell-specifically and reversibly
regulated by a doxycycline-inducible shRNA that targets the Cox2
transcript. In addition, we created a luciferase reporter knockin
mouse (Cox2tm2Luc), in which luciferase replaces the coding region
of the endogenous Cox2 gene, while retaining all Cox2 regulatory
regions (promoter, 59UTR, 39UTR). Because shRNA Cox2.2058
targets a sequence in the Cox2 gene 39UTR, Cox2 gene-driven
luciferase activity can be used to monitor noninvasively Cox2.2058
shRNA-mediated COX-2 knockdown. Using the Cox2tm2Luc/+
heterozygous reporter mouse, investigators can quickly evaluate
the feasibility of the system for tissue or cell-specific applications.
Although the heterozygous Cox2tm2Luc/+ mouse provides a model
in which to quickly monitor Cox2 gene expression, many aspects of
COX-2 biology are gene-dosage dependent [28,47,48]. Since the
TG-Cox2.2058 transgene is present in only a single copy, it is
necessary to demonstrate substantial DOX-dependent COX-2
suppression in mice homozygous for the Cox2 wild type allele and,
more importantly, to confirm that COX-2 knockdown can result
in functional suppression. Both criteria are met for TPA-induced
skin inflammation (Fig. 6), a classic model of COX-2 induction
[49]. ShCox2 silencing of COX-2 expression resulted in a
significant reduction of leukocytes present in the dermis following
TPA treatment (Fig. 6C). This finding is consistent with previous
studies that show that COX-2 plays a role in leukocyte chemotaxis
[39,50]; Nakamura et al [39] found a ,40% reduction in
leukocyte infiltration following two TPA applications in the
presence of the COX-2 inhibitor nimesulide [39].
In our in vivo experiments (Figs. 4–6) we supply and withdraw
DOX in 12-day intervals. The literature suggests that DOX
induction and de-induction occurs more rapidly; e.g. 2–4 days
[24]. However, when monitoring GFP as a surrogate indicator for
shCox2 expression, we observed residual fluorescence for 10–12
days after DOX withdrawal. Additional experiments will be
needed to determine the relationship between the stability of the
GFP reporter and the stability of Cox2.2058 following DOX
removal, to optimize minimal times required for reversible,
Cox2.2058-mediated COX-2 expression knockdown and recov-
ery.
Measuring Cox2-driven luciferase activity confirmed that DOX-
regulated shCox2-dependent COX-2 silencing exhibited full
reversibility in the skin inflammation system (Fig. 5). The ability
to reversibly and repeatedly knock down Cox2 gene expression is
one of the greatest assets of the shCox2 gene silencing protocol; the
model has the enormous advantage of not permanently disrupting
the Cox2 gene. This property allows reversible manipulation of
COX-2 expression at any time after disease onset, permitting – for
example – investigation of the complex roles of COX-2 expression
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Figure 6. DOX-dependent suppression of TPA-induced COX-2 expression by shCox2 in mice homozygous for the Cox2 gene. (A)
Double transgenic shCox2/C3 mice, which have two wild type Cox2 alleles, were maintained on either a control (no DOX) or a DOX-supplemented
diet (+DOX) for 12 days, then painted with TPA on the back. 24 hours after TPA administration the mice were euthanized and skin extracts were
assayed for GFP and COX-2 protein by Western blotting. Quantification is from three independent experiments. The COX-2 signal was normalized to
the GAPDH loading control. Data are means +/2 S.D. (***p,0.001). (B) COX-2 (upper panels) and GFP (lower panels) immunohistochemistry in skin of
untreated shCox2/C3 mice (left panels), 24 hours after TPA administration to shCox2/C3 mice maintained on a DOX-free diet (center panels) and 24
hours after TPA treatment of shCox2/C3 mice maintained for 12 days on a DOX-supplemented diet (right panels). COX-2 staining is visible as brown
patches (white arrow) in the basal epithelium. (C) H&E stain to visualize leukocytes in skin sections from double transgenic shCox2/C3 mice treated
with TPA and/or DOX as in B. The graph depicts quantification of leukocytes in the dermis. Quantification is from two independent experiments. Data
are means +/2 S.D. (**p,0.01). The scale bar indicates 50 mm.
doi:10.1371/journal.pone.0101263.g006
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in alternative cells in inflammatory responses to pathogens, by
initiating knockdown in specific cell types at different time points
after infection. In contrast, conventional Cox2 gene disruption
permanently eliminates global COX-2 expression at all times.
Although conditional Cre recombinase expression can also be
induced at distinct time points by using the inducible Cre-ERT/
tamoxifen system, recombination irreversibly disrupts the target
locus. Moreover, Cre expression can, in some instances, show
significant toxicity [51]. In addition, shCox2 gene silencing
requires only two genes; a single TG-Cox2.2058 transgene and
the appropriate rtTA or tTA transactivator transgene; Cre-based
conditional deletion requires three alleles (two Cox2flox alleles and
the targeted Cre recombinase); consequently, shCox2 targeting
can be more easily and rapidly combined with existing mouse
disease models. The combination of easier genetic modeling and
repeated, reversible gene silencing should permit insights that go
beyond what can be obtained through conditional knockout
approaches. Another advantage of inducible shRNA gene
silencing which distinguishes it from the binary Cre-loxP system
is the possibility of graded inhibition of gene expression by varying
DOX dosage.
Suppression by shCox2 in distinct cell types requires appropri-
ate cell/tissue-specific rtTA/tTA transgenic mice. The list of such
mice is already extensive (ww.tetsystems.com), and growing. In
addition, a CAG promoter-driven lox-stop-lox conditional rtTA
transactivator that enables use of a Cre driver to convert
transgenic mice to a cell-specific rtTA setting is currently under
development (S. Lowe, submitted for publication).
Despite their great utility, RNAi-based gene regulation systems
have their limitations. Tetracycline analogues can have side effects
[52]. We included Luc+ control animals, to verify that COX-2
inhibition was due to shRNA expression, and not to DOX side
effects (Fig. S3). It is also important to ensure that DOX efficiently
reaches the target tissue of interest; DOX in the diet is more
effective than DOX supplied in the drinking water [53].
Adequate rtTA expression in the target tissue/cell type is a key,
rate-limiting step for DOX-regulated gene silencing. We chose the
CAG-rtTA3 transactivator, which shows particularly strong
expression in skin [24], to facilitate initial testing of the
Cox2.2058 shRNA. The CAG promoter is considered by many
to be ubiquitous. Because of our interest in inflammatory roles of
COX-2, we also analyzed luciferase activity in spleens and lungs of
IFN-c + LPS-treated triple transgenic mice. Luciferase expression
in the spleen or lung was not reduced significantly in IFN-c + LPS
treated mice that received a DOX-supplemented diet (Fig. S4).
Analysis of DOX-dependent shRNA expression in target cells is
facilitated by GFP co-expression. Consistent with previous reports
[24], we observed less than two-fold shRNA-coupled GFP
induction in spleen and lung by DOX, in contrast to the greater
than 10-fold GFP induction in skin. These results suggest that
CAG-driven rtTA3 transactivator expression may not be sufficient
to block COX-2 expression in all tissues, or that silencing of the
TRE-driven transgene may occur in some tissues, emphasizing the
importance of systematic validation of the system for each
application. Finally, it is important to keep in mind that, although
recent advances in design of the microRNA backbone have
significantly increased the effectiveness of single copy RNAi
molecules [54], tet-regulated RNAi can rarely produce the null
phenotype in individual cells achievable by gene deletion
strategies.
Inducible Cox2 gene knockdown using the tet-regulated shCox2
expression system provides a complementary approach to global
and conditional Cox2 gene knockout strategies to study COX-2
roles in vivo. Because COX-2 is inducible by a wide range of
stimuli and plays an important role in many disease states, the
double transgenic shCox2/C3 mouse and the triple transgenic
shCox2/C3/Luc+ mouse should become useful tools for the study
of the many aspects of COX-2 biology.
Supporting Information
Figure S1 (A) Percent of GFP expressing NIH 3T3 cells,
two days after LMP retrovirus vector transduction at a
low multiplicity of infection (MOI). Less than 1% of the cells
are GFP positive. The cells were harvested, washed with PBS,
fixed with 0.01% paraformaldehyde and analyzed by flow
cytometry to determine the percentage of GFP expression. Mock;
untransduced cells, indicating background fluorescence. Control;
cells transduced with a LMP vector encoding a control shRNA
against luciferase. Cox2.284 (1) – Cox2.3711 (4); cells transduced
with LMP vectors encoding Cox2 specific shRNAs 1–4. (B)
Schematic representation of the LMP retrovirus vector construct,
indicating the probe used for Southern blot (red) and restriction
enzyme target sites (X, XhoI. RI, EcoRI. HIII, HindIII. NI, NcoI).
(C–D) Southern blot of LMP vector transduced NIH 3T3 cells.
Cells were transduced at a low MOI. Two days later the cells were
treated with 2.5 mg/mL puromycin to select for LMP transduced
cells. Total DNA was harvested using the DNeasy kit (Qiagen).
Cell DNA was digested with restriction enzymes overnight, before
being subjected to Southern blot analysis. (C) Southern blot of
HindIII digested DNA from mock transduced NIH 3T3 cells (m) or
NIH 3T3 cells transduced with the LMP retrovirus vector
encoding control (c) or Cox2 specific shRNAs (1–4). HindIII
digestion results in a 1100 bp fragment within the vector
backbone, confirming the integrated LMP vector in cell genomic
DNA. (D) Southern blot of NcoI digested DNA from mock-
transduced (m), LMP control vector-transduced (c) or LMP vector
encoding Cox2.5078 shRNA (3)-transduced NIH3T3 cells. NcoI
has a single target site close to the 39 end of the LMP vector,
resulting in a ,1000+ bp fragment depending on the location of
the closest NcoI site in the cellular genome. The characteristic
smear on the Southern blot confirms multiple-sized DNA
fragments, indicating divers integration sites.
(TIF)
Figure S2 COX-2 and luciferase induction by interferon
gamma and endotoxin (IFN-c/LPS) in the hearts, livers
and lungs of heterozygous Cox-2tm2Luc/+ mice. Four mice
were injected i.p. with IFNc followed two hours later with LPS, or
with saline. After 6 hours, mice were euthanized, tissues were
removed and luciferase bioluminescence was quantified by
bioluminescence imaging (left panels). Tissue extracts were then
prepared and luciferase enzymatic activity was measured. COX-2
protein expression in tissue extracts was also analyzed by
immunoblotting (right panels). Data are means +/2 SD (**, p,
0.01; *, p,0.05).
(TIF)
Figure S3 (A) Luc+ mice that receive a DOX containing
diet (indicated in blue) have similar luciferase expres-
sion in the zymosan treated paws at 6 hours compared
to triple transgenic (shCox2/C3/Luc+) mice that do not
receive a DOX containing diet (indicated in red),
confirming that DOX treatment alone does not signifi-
cantly reduce luciferase expression. Data are means +/2
SD, *p,0.05. (B) DOX in the diet does not affect TPA-induced
Cox2-driven luciferase expression in skin. Luc+ mice were
maintained either on a DOX-free diet or on a DOX-supplement-
ed diet for 12 days prior to TPA administration to the skin. In vivo
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luciferase bioluminescence was measured 24 hours later. Biolu-
minescence in response to TPA painting is not significantly
different in Luc+ control mice on DOX-free and DOX-
supplemented diets. Data are individual values and averages from
two mice.
(TIF)
Figure S4 (A) GFP fluorescence imaging of spleen and
lung tissue from triple transgenic shCox2/C3/Luc+
mice that received a DOX containing diet (+DOX) or a
control diet (no DOX) for 12 days. GFP fluorescence is
increased significantly, but not to a great extent in the spleens. In
the lungs, there was no significant difference in GFP fluorescence
between shCox2/C3/Luc+ mice on a DOX containing diet and
on a DOX free diet. (B) Luciferase induction by interferon
gamma and endotoxin (IFN-c/LPS) in the spleens and lungs of
triple transgenic shCox2/C3/Luc+ mice that were fed a DOX
containing diet (+DOX) to induce shRNA expression or a control
diet (no DOX) for 12 days. Mice were injected i.p. with IFNc
followed two hours later with LPS, or with saline (mock). After 6
hours, mice were euthanized, tissues were removed and luciferase
bioluminescence was quantified by bioluminescence imaging.
Luciferase expression was not significantly different in mice
receiving the DOX diet versus controls. Data are means +/2
SD. (*, p,0.05, ns, p.0.05, n= 4).
(TIF)
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